BridgeBio is hiring an HCP marketer to "identify doctors that have, or are most likely to have LGMD2I/R9 patients" and to evolve the disease education campaign. Its own site shows the gap: for ADH1, BridgeBio runs sponsored testing with a kit order form, prepaid return postage and on-demand mobile sample collection; for LGMD2I/R9, the HCP page says BridgeBio "does not directly provide a testing program" and sends doctors to two outside programs. In a condition where diagnosis can take 10+ years and genetic testing is the only way to confirm it, the testing step is where undiagnosed patients are found.
First action
Put the ADH1 and LGMD2I/R9 HCP testing pages side by side and list what the LGMD page is missing.
How to measure it
Testing-order clicks from the LGMD2I/R9 HCP page
- Now
- –
- Target
- 3x baseline
- By
- 90 days
Steps
Compare the two programs
Kit ordering, mobile collection, eligibility, turnaround and support for ADH1 vs LGMD2I/R9.
Associate Director, HCP Marketing 2 days
Write the checklist
When to suspect a genetic LGMD and order testing, from published guidance.
Medical Affairs 2 weeks
Rebuild the page
One primary action, both programs side by side, plain eligibility.
Digital Marketing team 2 weeks
Assess a sponsored option
Kit and mobile collection like DetectHypopara, under program rules.
Healthcare Compliance 1 month
Track orders
Tagged links and program-reported totals, aggregated by clinic type only.
Associate Director, Omnichannel Analytics 1 week
Equip the field
Leave-behind and QR link for clinic visits and speaker programs.
Neuromuscular Account Manager 2 weeks
Review monthly
Orders, diagnostic yield and clinic coverage.
Associate Director, HCP Marketing monthly
Why it works
Rebuild the LGMD2I/R9 HCP testing page around one action: order a no-cost test. Add a short "when to suspect a genetic LGMD" checklist reviewed by Medical Affairs, one-click links into both sponsored programs with clear eligibility, and, with Compliance, evaluate a BridgeBio-sponsored kit and mobile-collection option like DetectHypopara. Promote the page to neuromuscular clinics through the field team, speaker programs and medical meetings, and measure tracked order clicks by clinic type. Keep it unbranded disease education.
Every diagnosis made today helps patients and their doctors whatever happens next, and the testing page is the most useful thing a neuromuscular clinic can be sent. The same step shows the HCP team which clinics are actively testing, which is exactly the targeting question the new role is asked to answer.
Ready to use
ChecklistLGMD2I/R9 HCP testing page
[ ] One headline action: order a no-cost genetic test [ ] When to suspect a genetic LGMD (Medical Affairs reviewed) [ ] Both sponsored programs, eligibility and turnaround side by side [ ] Option for kit or mobile collection (if approved) [ ] What to do after a result: genetic counseling, advocacy organizations [ ] Tracked links per channel [ ] Unbranded, HCP-only, reviewed by Compliance
Risks and how to handle them
Testing program seen as an inducement
Keep testing independent of any prescribing; follow Compliance rules for sponsored programs.
Partner programs change terms
Review the links and eligibility every quarter.
Evidence
- HiringAssociate Director, HCP Marketing (San Francisco, posted September 11, 2026): will "lead the development and execution of tactics supporting the commercial launch of BBP-418"; "develop tactics that will help identify doctors that have, or are most likely to have LGMD2I/R9 patients"; "Manage and evolve the disease education campaign and educational resources"; run the speaker bureau and "the creation of all HCP peer-to-peer educational content"; "Develop targeted measurement plans".Source
- Your websiteLGMD2I/R9 genetic testing page for healthcare professionals: "While BridgeBio does not directly provide a testing program for LGMD2I/R9 at this time, we are committed to helping you find the resources you need." It links out to two third-party sponsored programs (Detect Muscular Dystrophy and The Lantern Project), and notes that "cardiac and respiratory involvement is more common" than in other subtypes and that there are "over 30 identified LGMD subtypes".Source
- Your websiteADH1 testing, by contrast, is BridgeBio-run: "DetectHypopara Sponsored Testing" with Prevention Genetics, an HCP test kit order form ("Kits will include pre-paid return postage") and an option to "Schedule an on-demand test", plus patient and HCP pages for ADH1 and hypoparathyroidism.Source
- Your websiteLGMD2I/R9 condition page: "7,000+ estimated individuals living with LGMD2I/R9 in the U.S. and Europe"; "As many as 10+ years to receive diagnosis due to variability of symptoms"; "Genetic testing is the only way to confirm a diagnosis of LGMD2I/R9."Source
- HiringLaunch field and access roles open now: a Neuromuscular Account Manager (Mid-Atlantic, posted October 23, 2026) with "subject matter expertise concerning scientific and clinical information for BBP-418"; a Commercial Learning & Development Associate Director as "training lead for the product launch"; a Regional Sales Director - Attruby; and Managed Markets directors (national and regional accounts) supporting "launch and post-launch strategies across the BBIO portfolio".Source